Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) have been assigned an average recommendation of “Buy” from the eight analysts that are currently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $23.00.
Several equities analysts have commented on ACRV shares. BMO Capital Markets began coverage on shares of Acrivon Therapeutics in a report on Monday, May 8th. They issued an “outperform” rating and a $25.00 target price on the stock. HC Wainwright began coverage on shares of Acrivon Therapeutics in a report on Thursday, April 20th. They set a “buy” rating and a $24.00 price target on the stock. Oppenheimer began coverage on shares of Acrivon Therapeutics in a report on Thursday, June 1st. They set an “outperform” rating and a $25.00 price target on the stock. Finally, LADENBURG THALM/SH SH began coverage on shares of Acrivon Therapeutics in a report on Thursday, April 27th. They set a “buy” rating and a $22.00 price target on the stock.
Acrivon Therapeutics Price Performance
ACRV stock opened at $11.75 on Friday. Acrivon Therapeutics has a 12 month low of $8.06 and a 12 month high of $25.47. The company’s 50-day moving average price is $12.49 and its two-hundred day moving average price is $14.23.
Institutional Investors Weigh In On Acrivon Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. acquired a new stake in Acrivon Therapeutics during the 4th quarter worth approximately $55,417,000. Sands Capital Ventures LLC acquired a new position in shares of Acrivon Therapeutics in the 4th quarter worth approximately $19,038,000. Marshall Wace LLP acquired a new position in shares of Acrivon Therapeutics in the 4th quarter worth approximately $14,092,000. NEA Management Company LLC acquired a new position in shares of Acrivon Therapeutics in the 4th quarter worth approximately $4,439,000. Finally, BlackRock Inc. acquired a new position in shares of Acrivon Therapeutics in the 1st quarter worth approximately $6,018,000. 69.41% of the stock is currently owned by institutional investors and hedge funds.
Acrivon Therapeutics Company Profile
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Featured Articles
- Five stocks we like better than Acrivon Therapeutics
- Conference Calls and Individual Investors
- 3 Best Meme ETFs to Buy Now
- What is the FTSE 100 index?
- XPO Keeps Reaching New Highs: Markets Love the Stock
- What is Short Interest? How to Use It
- Starbucks Market at a Turning Point: Is a Breakout Imminent?
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
